Barclays reiterates Overweight on BridgeBio Pharma stock at $157

Barclays reiterated an Overweight rating on BridgeBio Pharma with a $157 price target versus the current $70.62 share price, implying substantial upside. The key catalyst is reduced patent uncertainty around tafamidis, as Pfizer and Aurobindo stipulated dismissal of their IP case, which may support BridgeBio’s Attruby launch timing ahead of generic competition. Other analysts remain constructive, with TD Cowen at $95, RBC at $100, William Blair at Outperform, and Mizuho at $106.

Analysis

BBIO is trading less like a single-asset biotech and more like a legal-duration trade: the market is now assigning a cleaner runway to Attruby before a generic tafamidis overhang can materially compress the addressable pool. The key second-order effect is not just “more upside,” but a higher probability of multiple expansion as investors stop discounting an imminent cliff and begin capitalizing launch execution, diagnosis growth, and share capture against an aging, underdiagnosed market.

The harder read is PFE. The settlement clarity helps remove binary litigation noise, but it also signals that the franchise is entering a managed decline rather than a sudden collapse. That tends to make the loser slower and more distributable: rather than an overnight revenue shock, expect a gradual erosion curve that can still support cash flow while opening the door for newer entrants to win on convenience and physician behavior. Any delay in diagnosis conversion or payer pushback would matter more than patent timing at this point.

The biggest missed angle is that the setup is likely underestimating commercialization risk in the next 2-4 quarters. BBIO needs awareness, cardiology screening, and payer pull-through to turn legal clarity into durable prescription growth; if any one of those lags, the stock can give back a meaningful fraction of the rerating. Conversely, if attrition at the incumbent accelerates faster than modeled, consensus could be too conservative on peak share assumptions, making the current setup still under-owned.

This looks best expressed as a medium-dated catalyst trade rather than a pure long-term fundamental hold. The asymmetry is strongest while the market is repricing probability around launch timing and competitive durability; once the narrative shifts to execution metrics, dispersion between BBIO and PFE should widen.

Key Decisions for Investors

• Long BBIO vs short PFE as a 3-6 month pair trade: BBIO should benefit from legal clarity and rerating, while PFE absorbs gradual franchise decay; target 1.5-2.0x downside capture on the short leg relative to the long.
• Buy BBIO on pullbacks toward the low-70s with a 3-6 month horizon; risk/reward remains attractive if the market continues to price in cleaner Attruby launch timing before generic pressure becomes visible in prescriptions.
• Use BBIO call spreads instead of outright equity for event-driven upside: consider 4-6 month maturities to express rerating potential while capping downside if awareness or payer adoption underwhelms.
• Fade any sharp short-covering bounce in PFE unless accompanied by improved commercial signals; this is a slow-burn competitive erosion story, not a litigation win that restores growth.